SNH-119014 / ScinnoHub, Chengdu Brilliant Pharma - LARVOL DELTA

A Study of SNH-119014 in Adult Participants With Non-transfusion-dependent Thalassemia (NTDT) (clinicaltrials.gov) - P2 | N=30 | Not yet recruiting | Sponsor: ScinnoHub Pharmaceutical Co., Ltd.

New P2 trial • Genetic Disorders

SNH-119014, a novel pyruvate kinase activator, enhances ATP production and reduces oxidative stress in erythroid cells from patients with β-thalassemia major. (PubMed, Front Pharmacol) - "SNH-119014 is a novel allosteric PK activator targeting the same protein as mitapivat (AG-348), a first-in-class agent known to ameliorate anemia in thalassemia. In conclusion, SNH-119014 activates PK, thereby increasing ATP production and alleviating oxidative stress in erythroid cells from β-TM patients. SNH-119014 exhibits a promising pharmacological profile, supporting its further development as a potential therapy for thalassemia."

Journal • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • CD34

Snh-119014, a novel pyruvate kinase activator, enhances ATP production and reduces oxidative stress in erythroid cells from patients with β-thalassemia major (ASH 2025) - "SNH-119014 activates PK, increases ATP production, and alleviates oxidative stress inerythroid cells from β-TM patients. Its comparable efficacy to AG-348 in ex vivo systems supports SNH-119014 as a promising candidate for therapeutic development in thalassemia."

Clinical • Oxidative stress • Anemia • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • CD34